PATENT CLAIM ANALYSIS

Application Number: 16216701
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-11
Patent Classification: ["514", "252130"]

Abstract:
The invention relates to a serotonin receptor (5-HTR) inhibitor selected from the group consisting of a type 1 5-HTR inhibitor and a type 2 5-HTR inhibitor for use in the prevention and/or treatment of a haematological malignancy. Additionally, the invention relates to in vitro methods for the identification or isolation of a malignant cell from a haematological malignancy or for diagnosing a haematological malignancy based on detecting the expression of type 1 5-HTR and/or type 2 5-HTR. Furthermore, the invention relates to in vitro methods for determining the prognosis, for monitoring the effect of a therapy or for designing a customized therapy in a subject suffering from a haematological malignancy based on determining the levels of type 1 5-HTR and or type 2 5-HTR.

Claim (Index 22):
The method according to  claim 15 , wherein the blood sample is peripheral blood.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 98.0
- Lexical Diversity: 2.4
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15322012', '14113518', '15528807', '14934276', '14440744']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7328894051318371
- 35 USC 102 Novelty (BERT): 0.5959092928456025
- Combined Prediction Score: 0.7191913939032136
- Mean Citation Score: 315.39195600000005
- Max Citation Score: 636.34875
- Similarity Product: 385.013308340013

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test